8-K: OmniAb Reports Mixed Q4 and Full Year 2024 Results; Provides 2025 Guidance

OmniAb reported its Q4 and full year 2024 financial results, highlighting revenue increases in Q4 but a decrease for the full year, and introduced its 2025 financial guidance.

Summary

• OmniAb reported a Q4 2024 revenue of $10.8 million, up from $4.8 million in Q4 2023, driven by higher license and milestone revenue.
• The company's Q4 2024 net loss was $13.1 million, or $0.12 per share, compared to a net loss of $14.1 million, or $0.14 per share, for the same period in 2023.
• Full year 2024 revenue was $26.4 million, down from $34.2 million in 2023, primarily due to the recognition of a $10.0 million TECVAYLI milestone in 2023.
• The full year 2024 net loss was $62.0 million, or $0.61 per share, compared to a net loss of $50.6 million, or $0.51 per share, for 2023.
• As of December 31, 2024, OmniAb had $59.4 million in cash, cash equivalents, and short-term investments.
• OmniAb expects 2025 revenue to be in the range of $20 million to $25 million and operating expense to be in the range of $90 million to $95 million.
• The company anticipates lower cash use in 2025 compared to 2024, with 2024 cash use being $38.9 million excluding ATM issuance.
• As of December 31, 2024, OmniAb had 91 active partners and 363 active programs, including 32 OmniAb-derived programs in clinical development or being commercialized.
• The company signed 10 new license agreements in 2024, including two in the fourth quarter with Incyte Corporation and Photinia Biosciences.
• Five new OmniAb-derived antibodies entered the clinic in 2024.
• In December 2024, OmniAb launched OmniHub, a unified interface for partners to access and visualize discovery campaign data.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While Q4 results showed improvement, the full year results were down compared to the previous year. The company is guiding for lower revenue in 2025, but expects to reduce cash burn. The company has a strong base of partners and programs, and is innovating with the launch of OmniHub.

Positives

• Q4 2024 revenue increased significantly compared to Q4 2023.
• Net loss decreased in Q4 2024 compared to Q4 2023.
• The company has a substantial number of active partners and programs.
• OmniAb signed 10 new license agreements in 2024.
• Five new OmniAb-derived antibodies entered the clinic in 2024.
• The launch of OmniHub provides partners with enhanced data access and visualization capabilities.
• Cash use is expected to be lower in 2025 compared to 2024.

Negatives

• Full year 2024 revenue decreased compared to 2023.
• Net loss increased for the full year 2024 compared to 2023.
• Royalty revenue decreased primarily due to lower net product sales by partners.

Risks

• OmniAb's future success depends on the acceptance of its technology platform by new and existing partners.
• The company's success is contingent on the eventual development, approval, and commercialization of products developed by its partners, over which OmniAb has no control.
• Biopharmaceutical development is inherently uncertain.
• Changes in technology and the competitive environment in the life sciences and biotechnology platform market pose risks.
• Failure to maintain, protect, and defend intellectual property rights could adversely affect the company.
• Unstable market and economic conditions may have serious adverse consequences on the business, financial condition, and stock price.
• The company may use its capital resources sooner than expected.

Future Outlook

OmniAb expects 2025 revenue to be in the range of $20 million to $25 million and operating expense to be in the range of $90 million to $95 million; the company also expects 2025 cash use to be lower than its cash use in 2024.

Management Comments

• Matt Foehr, Chief Executive Officer of OmniAb, stated that 2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs.
• Matt Foehr believes that the company's commitment to innovation is a significant competitive advantage and creates exciting opportunities for future growth.
• Matt Foehr stated that the company remains steadfast in its strategic direction and is excited about the prospects that lie ahead.

Industry Context

OmniAb operates in the competitive biotechnology platform market, licensing its technology to pharmaceutical and biotech companies for antibody discovery; the company's success is tied to the progress of its partners' drug development programs and the overall demand for innovative antibody discovery solutions.

Comparison to Industry Standards

• It's difficult to directly compare OmniAb's financial performance to industry standards without knowing the specific details of its licensing agreements and the stage of development of its partners' programs.
• However, companies like Ligand Pharmaceuticals and Royalty Pharma operate on similar royalty-based models, and their financial performance could be used as a benchmark.
• The number of active partners and programs (91 and 363, respectively) suggests a strong level of engagement with the biopharmaceutical industry.
• The company's focus on innovation and the launch of OmniHub indicate a commitment to staying competitive in the rapidly evolving antibody discovery market.

Stakeholder Impact

• Shareholders: The mixed financial results and 2025 guidance may impact shareholder value.
• Employees: The company's strategic direction and growth prospects could affect employee morale and job security.
• Partners: The company's technology platform and services impact the success of its partners' drug development programs.
• Customers: The company's partners' drug development programs ultimately impact patients who may benefit from new therapies.

Next Steps

• Immunovant is on track to initiate potentially registrational programs for three additional indications for IMVT-1402 by March 31, 2025.
• Immunovant expects top-line results of the batoclimab trial in myasthenia gravis and the initial results from period 1 of the batoclimab trial in chronic inflammatory demyelinating polyneuropathy by March 31, 2025.
• Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of 10 indications by March 31, 2026.
• Immunovant plans to announce additional data from the batoclimab proof-of-concept study in GD, including six-month, treatment-free remission data in the summer 2025.
• Immunovant expects top-line results from the pivotal program of batoclimab for the treatment of thyroid eye disease (TED) in the second half of 2025.
• Genmab expects to provide an additional Phase 2 data update in NSCLC in 2025.
• Arcus Biosciences expects to present overall survival (OS) data from the Phase 2 EDGE-Gastric study in the fall of 2025.
• Arcus Biosciences expects to initiate three new expansion cohorts within the Phase 1/1b ARC-20 study in the first quarter of 2025.
• Aptevo Therapeutics anticipates providing multiple data readouts in 2025 and presenting results at the American Society of Hematology meeting in the fourth quarter of 2025.
• Rondo Therapeutics expects to initiate a Phase 1/b trial for RNDO-564 in relapsed/refractory, locally advanced/metastatic bladder cancer by year-end 2025.

Key Dates